1,714 results match your criteria: "Movement Disorders Clinic.[Affiliation]"
Mov Disord Clin Pract
January 2025
Department of Neurology, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
Parkinsonism Relat Disord
January 2025
Edmond J. Safra Program in Parkinson's Disease, Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada; Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Neurology, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
J Mov Disord
November 2024
Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno (SA), 84131, Italy.
Mov Disord Clin Pract
November 2024
Center for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, Ontario, Canada.
Mov Disord Clin Pract
January 2025
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Background: Reduced cerebrospinal fluid (CSF) clearance may play a vital role in the pathogenesis of normal pressure hydrocephalus (NPH), but the radiologic marker is yet to be elucidated.
Objectives: This open-label study presents two novel neuroimaging biomarkers based on enlarged perivascular spaces (ePVS) of the sub-insular territory: the Hedgehog and Hedgehog-Halo (H-H) sign, designed to predict gait symptom severity and tap response in NPH.
Methods: We retrospectively reviewed 203 patients with possible NPH with baseline magnetic resonance imaging and gait analyses before and after lumbar puncture (LP).
Neurology
December 2024
From the Division of Neurology (O.E.A., A.R.), Department of Medicine, University of Toronto; Division of Neurology (N.C.S.), Mount Sinai Hospital, Joseph and Wolf Lebovic Centre; Division of Neuroradiology (D.M.M.), Department of Medical Imaging, University Health Network; Edmond J. Safra Program in Parkinson's Disease (A.F.), Division of Neurology, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, University of Toronto; and Krembil Brain Institute (A.F.), Toronto, Ontario, Canada.
Eur J Neurol
January 2025
Department of Neurology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Background And Purpose: Patients with episodic ataxia type 2 (EA2) suffer from recurrent paroxysmal episodes of vertigo and oscillopsia. Pathophysiologically, altered neuronal excitability has been suspected. Vestibular excitability in 22 EA2 patients and 22 age-matched healthy participants was compared.
View Article and Find Full Text PDFMov Disord Clin Pract
January 2025
Laboratory of Clinical Pharmacology, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Background: The MDS-UPDRS has been available in English since 2008, showing satisfactory clinimetric results and being proposed as the new official benchmark scale for Parkinson's disease (PD), being cited as a core instrument for PD in the National Institutes of Neurological Disorders and Stroke Common Data Elements program. For this reason, the MDS created guidelines for development of MDS-UPDRS official, clinimetrically validated translations.
Objective: This study presents the formal process used to obtain the officially approved Portuguese version of the MDS-UPDRS.
Mov Disord
January 2025
Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada.
Background: Orthostatic tremor (OT) is a rare movement disorder characterized by a feeling of unsteadiness and a high-frequency tremor in the legs (13-18 Hz) relieved by sitting or walking.
Objectives: The aims were to study the brain electrophysiology captured chronically in a person with medication-refractory OT while standing and walking and in the semi-recumbent position using bilateral ventral intermedius nucleus deep brain stimulation (DBS) (Medtronic Percept PC) and to describe the clinical use of closed-loop DBS.
Methods: A sensing survey was used to capture baseline local field potentials (LFPs) while standing.
Front Neurosci
October 2024
Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Expert Opin Drug Saf
December 2024
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
Introduction: Drug-induced parkinsonism (DIP) is one of the most common iatrogenic movement disorders. It is characterized by tremors, slowness of movement, and shuffling gait with postural instability, clinically indistinguishable from idiopathic Parkinson's disease. Prior exposure to antipsychotic medications or other dopamine receptor blocking agents (DRBAs) is required for the diagnosis.
View Article and Find Full Text PDFNeurorehabil Neural Repair
January 2025
Laboratory of Neuromuscular Adaptations to Strength Training, School of Physical Education and Sport, University of São Paulo, SP, Brazil.
Curr Neuropharmacol
October 2024
Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Via F.Cervi 93, Segrate, Milan, Italy.
Objective: Temporal lobe epilepsy (TLE) is the most common form of refractory focal epilepsy, and the current clinical diagnosis is based on EEG, clinical neurological history and neuroimaging findings.
Methods: So far, there are no blood-based molecular biomarkers of TLE to support clinical diagnosis, despite the pathogenic mechanisms underlying TLE involving defects in the regulation of gene expression. MicroRNAs (miRNAs) have emerged as important post-transcriptional regulators of gene expression.
Neurol Clin Pract
February 2025
Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic (AB, AF), Toronto Western Hospital, UHN, Division of Neurology, University of Toronto; Krembil Brain Institute (AF); and Center for Advancing Neurotechnological Innovation to Application (CRANIA) (AF), Toronto, Ontario, Canada.
Neurol Clin Pract
February 2025
Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX.
medRxiv
September 2024
"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milan, Italy.
Cerebellum
December 2024
IRCCS Neuromed, Pozzilli (IS), Italy.
Nat Rev Neurol
December 2024
Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Res Sq
September 2024
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Pathogenic variants in the gene represent the most common cause of autosomal dominant Parkinson's disease (PD) worldwide. We identified the p.L1795F variant in 14 White/European ancestry PD patients, including two families with multiple affected carriers and seven additional affected individuals with familial PD using genotyping and sequencing data from more than 50,000 individuals through GP2, AMP-PD, PDGENEration, and CENTOGENE.
View Article and Find Full Text PDFJ Parkinsons Dis
October 2024
Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada.
JCI Insight
November 2024
Department of Microbiology and Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Despite growing recognition, neuropsychiatric diseases associated with infections are a major unsolved problem worldwide. Group A streptococcal (GAS) infections can cause autoimmune sequelae characterized by movement disorders, such as Sydenham chorea, and neuropsychiatric disorders. The molecular mechanisms underlying these diseases are not fully understood.
View Article and Find Full Text PDFJ Neurol
November 2024
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
NPJ Parkinsons Dis
September 2024
Department of Neurology and Neurological Sciences, Stanford University, Stanford, USA.
Adaptive deep brain stimulation (aDBS) is an emerging advancement in DBS technology; however, local field potential (LFP) signal rate detection sufficient for aDBS algorithms and the methods to set-up aDBS have yet to be defined. Here we summarize sensing data and aDBS programming steps associated with the ongoing Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) pivotal trial (NCT04547712). Sixty-eight patients were enrolled with either subthalamic nucleus or globus pallidus internus DBS leads connected to a Medtronic Percept PC neurostimulator.
View Article and Find Full Text PDFParkinsonism Relat Disord
November 2024
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA. Electronic address:
NPJ Parkinsons Dis
September 2024
Krembil Brain Institute, University Health Network, Toronto, ON, Canada.
Parkinson's disease (PD) has been associated with pathological neural activity within the basal ganglia. Herein, we analyzed resting-state single-neuron and local field potential (LFP) activities from people with PD who underwent awake deep brain stimulation surgery of the subthalamic nucleus (STN; n = 125) or globus pallidus internus (GPi; n = 44), and correlated rate-based and oscillatory features with UPDRSIII off-medication subscores. Rate-based single-neuron features did not correlate with PD symptoms.
View Article and Find Full Text PDF